GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Cirrhosis Liver/Psychomotor Speed and Frailty in Advanced Liver Disease: AJG | April 2026
32

Psychomotor Speed and Frailty in Advanced Liver Disease: AJG | April 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated April 1, 2026

Introduction

Minimal hepatic encephalopathy (MHE) and physical frailty are highly prevalent yet often under-recognised complications in patients with advanced chronic liver disease (AdvCLD). While MHE reflects subtle neurocognitive impairment, frailty represents systemic physical vulnerability. Traditionally, complex tools like the Psychometric Hepatic Encephalopathy Score have limited routine clinical assessment of MHE. The simpler Stroop EncephalApp (StE) offers a practical alternative, raising interest in understanding how cognitive dysfunction—particularly psychomotor speed—relates to physical frailty.

Problem Statement

Despite both MHE and frailty being strong predictors of poor outcomes, their interrelationship remains poorly defined. Specifically, it is unclear whether cognitive impairment assessed by simple tools like StE correlates meaningfully with frailty indices and whether this relationship can be used for risk stratification in clinical practice.

Summary

In this multicenter study of patients awaiting liver transplantation, MHE was present in 73% and frailty in 18%. Patients with MHE had significantly worse Liver Frailty Index (LFI) scores and were more frequently classified as prefrail or frail. A strong correlation was observed between psychomotor speed—particularly StE off-time—and frailty, with LFI independently predicting MHE (OR 2.41).

These findings highlight a critical brain–muscle axis in cirrhosis, where impaired psychomotor speed mirrors physical decline. The study supports the use of simple bedside tools like StE to identify high-risk patients and suggests that integrated cognitive and physical interventions may improve outcomes in advanced liver disease.

Related Q&A

33

Oral Health Matters in Cirrhosis: JHEP Reports/ March 2026

Introduction: Cirrhosis is increasingly recognised as a multisystem disease influenced by inflammation, microbiome alterations, and extrahepatic factors. Poor oral health, particularly periodontitis, contributes to systemic inflammation and bacterial...

34

Recompensation in Decompensated Cirrhosis: CGH/ April 2026

Introduction: Decompensated cirrhosis has traditionally been considered an irreversible stage of liver disease, associated with poor survival and frequent complications such as ascites, variceal bleeding, and hepatic encephalopathy....

35

Baclofen vs Acamprosate in Alcohol-Associated Cirrhosis: Alimentary Pharmacology & Therapeutics | March 2026

Introduction Management of alcohol use disorder in patients with cirrhosis remains a clinical challenge, where drug safety is as critical as efficacy. Acamprosate is generally preferred due to...

36

Early Portopulmonary Hypertension in Cirrhosis: Journal of Hepatology | February 2026

Introduction Portopulmonary hypertension represents a complex cardiopulmonary complication of cirrhosis that significantly impacts prognosis and transplant eligibility. Recent data from the PORTO-DETECT cohort have suggested that even early-stage...

37

Post-Banding Ulcer Bleeding After EBL: Alimentary Pharmacology & Therapeutics | March 2026

Introduction Endoscopic band ligation (EBL) remains the standard of care for managing esophageal varices, both in acute variceal bleeding and for prophylaxis. However, post-banding ulcer bleeding (PBUB) is...

38

Ammonia Measurement in Cirrhosis: Journal of Hepatology| March 2026

Introduction Ammonia has long been recognized as a central neurotoxin in the pathogenesis of hepatic encephalopathy, but its clinical use in cirrhosis has remained inconsistent because of major...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer